Heat Biologics stock soars 9% on supply contract with Canada for anthrax drug Anthimseekingalpha2022-04-27 21:51Heat Biologics+0.00%Heat Biologics+6.72%
TEL AVIV, Israel, April 28, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today interim results from the Open-Label Part of the ARMOR study showing fibrosis improvement with Aramchol using multimodality histological assessment
Brand Leaders: ORAGIN Foods, Warby Parker, Sundial Growers, and Kona Gold; Driving Revenue Growth with New Market Expansion, and Product Innovation in Specialty Retail, and Consumer BrandsWall Street ReporterTue, April 26, 2022, 9:48 PM·8 min read